Cediranib / AZD-2171 / 288383-20-0
Inquiry
| Post Date: | Aug 18,2016 |
| Expiry Date: | Aug 18,2017 |
| Detailed Description: |
Cas No. :288383-20-0
Quantity: 0.1Kilograms Specs:98%min Price:100 USD Kilograms Payment Method: T/T Cediranib (AZD-2171) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. On 8 March 2010, AstraZeneca issued a press-release stating that cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader bevacizumab. As of November 2012, it was being assessed in double-blind studies for the treatment of methylated Glioblastoma Multiforme at the University of Washington Medical Center. |
| CAS Registry Number: | 288383-20-0 |
| Synonyms: | ;4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; |
| Molecular Formula: | C25H27FN4O3 |
| Molecular Weight: | 450.5053 |
| Molecular Structure: | 
|
| Company: | Shanghai Biopharmaleader Co.,Ltd [ China ] |
| Contact: | Brenda Xu |
| Tel: | 021-50180596 |
| Fax: | 021-57758967 |
| Email: | brenda@biopharmaleader.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
